WALTHAM, Mass. , Jan. 15, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ: NURO) will issue its fourth quarter 2018 financial results on Thursday morning January 24, 2019 . A conference call will be held shortly afterwards at 8:00 a.m. Eastern. The call may be accessed in the United States at
WALTHAM, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix (Nasdaq: NURO) today announced a successful CES 2019, the world’s largest and most influential technology event, which took place January 8 – 11 in Las Vegas. Highlights of the week-long event include: Quell 2.0 Named CES Innovation
WALTHAM, Mass. , Jan. 22, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) today reported publication of results from a randomized controlled trial of Quell ® in subjects with chronic low back pain in the journal Pain Practice. The paper is titled “ Outcome of a High Frequency
WALTHAM, Mass. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter and year ended December 31, 2018 . The Company develops and markets novel therapies for chronic health conditions employing neurostimulation and
WALTHAM, Mass. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported publication of three new DPNCheck ® clinical studies. DPNCheck is a point-of-care test that provides accurate and cost-effective screening, diagnosis and monitoring of diabetic peripheral neuropathy
WALTHAM, Mass. , April 17, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that it plans to issue its 2019 first quarter financial results before the opening of the market on Thursday, April 25, 2019. The Company will host a conference call at 8:00 a.m., Eastern
WALTHAM, Mass. , April 25, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO ), today reported financial and business highlights for the quarter ended March 31, 2019 . The Company develops and markets novel therapies for chronic health conditions employing neurostimulation and digital
WALTHAM, Mass. , May 07, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,279,179 titled “Transcutaneous Electrical Nerve Stimulator with automatic detection of user sleep-wake state.” The patent covers
WALTHAM, Mass. , May 21, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,293,159 titled “Measuring the ‘on-skin’ time of a Transcutaneous Electrical Nerve Stimulator (TENS) device in order to minimize
WALTHAM, Mass. , June 27, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), a health technology company addressing chronic health conditions including chronic pain, sleep disorders and diabetes, today reported on its strategy of optimizing its commercial products while reducing operating
